Evidence map›Paper›PMID 41793692›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2026

Schlafen 11 (SLFN11) And Tumor-Infiltrating Lymphocytes (TILs): Dual Predictive Biomarkers In Ovarian Serous Carcinoma.

Sherry R Michael, Dalia M Badary, Hisham Ahmed Abou-Taleb, Doaa A Gamal, Rabab Mohamed Mumdouh, Youssab A F Nazeer, Mahmoud I Nassar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sherry R MichaelPathology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.ORCID 0009-0008-9925-329X
Dalia M BadaryPathology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.ORCID 0000-0003-0252-7175
Hisham Ahmed Abou-TalebGynecologic Oncology Unit, Department of Obstetrics and Gynecology, Women Health Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt.
Doaa A GamalClinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Rabab Mohamed MumdouhDepartment of Medical Oncology and Hematological Malignancy, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Youssab A F NazeerHouse Officer at Assiut University Hospitals, Faculty of Medicine, Assiut University, Assiut, Egypt.
Mahmoud I NassarPathology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to investigate the clinicopathological significance and prognostic impact of SLFN11 expression and tumor-infiltrating lymphocytes (TILs) in high-grade and low-grade ovarian serous carcinoma.

methodsA total of 70 patients diagnosed with high-grade and low-grade serous carcinoma were retrospectively analyzed. Clinical data, including age, Karnofsky Performance Status (KPS), CA125 levels, treatment details, and survival outcomes, were collected. Immunohistochemistry was used to assess SLFN11 expression in tumor cells and TILs. Statistical correlations were performed with chemotherapy response, recurrence, progression-free survival (PFS), and overall survival (OS).

resultsHigh SLFN11 expression was significantly associated with better response to neoadjuvant chemotherapy (p = 0.003), higher histopathologic chemotherapy response score (p = 0.026), lower recurrence rate (p = 0.037), and improved survival outcomes (p < 0.001). High SLFN11 expression had significantly longer PFS (median= 33.05 months) and OS (median= 66.91 months), compared to those with low SLFN11 expression (median PFS =7.60 and median OS = 31.50, p<0.001). Similarly, high TILs count was associated with improved response to neoadjuvant chemotherapy (p = 0.008) and higher response score (p = 0.007). TILs-high patients had longer median PFS (25.52 months) and median OS (68.24 months) than TILs-low patients (median PFS = 10.30 and median OS = 30.63 months, p<0.001).

conclusionOur findings highlight that immunohistochemical expression of SLFN11 and the density of TILs may serve as predictive biomarkers for chemotherapy response and survival in ovarian serous carcinoma, with potential implications for personalized treatment strategies.

Indexed as

Biomarkers, TumorCystadenocarcinoma, SerousLymphocytes, Tumor-InfiltratingNeoplasm Recurrence, LocalNuclear ProteinsOvarian NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHumansMiddle AgedNeoadjuvant TherapyPrognosisRetrospective StudiesBiomarkers, TumorNuclear ProteinsSLFN11 protein, humanovarian serous carcinomapredictive biomarkersSchlafen 11 (SLFN11)survivalTumor-Infiltrating Lymphocytes (TILs)

Identifiers

PMID41793692
PMCPMC13576481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.